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Abstract
A prospective two dimensional and Doppler
echocardiographic study of 70 consecutive
patients with systemic lupus erythematosus
(SLE) and 40 controls was carried out. Forty
patients (57%) were found to have echocardio-
graphic disturbances. Valvular abnormalities
were detected in 31 patients (44%) and in only
two controls (5%). Mitral valve abnormalities
were the most common findings (23/70 (33%))
with mild or moderate regurgitation the most
frequent lesion (16% and 9% respectively).
Three patients (4%) had a morphological
echocardiographic pattern suggestive of non-
infective verrucous vegetations affecting the
mitral valve. No patient had haemodynamically
significant clinical valve disease. Pericardial
effusion was identified in 19 patients (27%), of
whom 14 had mild and clinically silent disease.
Myocardial abnormalities were found in 14
patients (20%), but clinical features of
myocardial dysfunction were present in only
one. Patients with antiphospholipid anti-
bodies were found to have an increased
prevalence of endocardial lesions, mainly
valvular regurgitation. It is concluded that the
inclusion of echocardiography in a study
protocol of patients with SLE can identify an
important subset of patients with cardiac
abnormalities, many of which are clinicaily
silent. In addition, the association of anti-
phospholipid antibodies with endocardial
lesions suggests that these antibodies may
have a prominent role in the pathogenetic
mechanisms of heart valve disease in SLE.
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Systemic lupus erythematosus (SLE) is an
autoimmune disorder resulting in multisystemic
inflammatory damage. Because of the pleo-
morphic nature of this disease its cardiac
manifestations have not always been emphasised.
In recent years, however, with prolonged
survival and improvement in diagnostic tech-
niques, the cardiac disease associated with SLE
has become more apparent. 1 2
The most characteristic cardiac abnormalities
in SLE are non-infective vegetations (Libman-
Sacks endocarditis). Although they are present
in up to 50% of patients at necropsy,3 4 reports
of their presence before death are uncommon.
In addition, pericarditis is a very common
clinical manifestation in SLE, occurring in 20 to
30% of all patients.5 Conversely, myocardial
lesions have been rarely documented. Never-
theless, recent introduction of two dimensional
and Doppler echocardiography has disclosed a
higher prevalence of patients with cardiac
abnormalities than previously reported-many
of them clinically silent and without manifes-
tations of SLE activity.61
In the past few years reports have linked the
presence of antiphospholipid antibodies-that
is, anticardiolipin antibodies and the lupus
anticoagulant, with cardiac lesions, such as non-
infective vegetations and valvular dysfunc-
tions."-"' Nevertheless, prospective studies of
large numbers of unselected patients are few
and no definite conclusions have been reached.
Therefore, our study aimed at describing the
prevalence of cardiac lesions in a large living
group of unselected patients with SLE by
means of two dimensional and Doppler echo-
cardiography, and analysing their relation with
clinical features of cardiopathy, lupus activity,
and the presence of antiphospholipid anti-
bodies.
Patients and methods
PATIENTS AND CONTROLS
Seventy consecutive white patients with SLE
(64 women, six men) attending the Hospital
Clinic of Barcelona as inpatients or outpatients,
between 1986 and 1989, were studied prospec-
tively. The average age of the patients was 38
(SD 15) years (range 8-73). All patients were
questioned by a qualified cardiologist about a
history of previous rheumatic fever, infective
endocarditis, hypertension, pleuritic or anginal
chest pain, and dyspnoea. A conventional
cardiovascular physical examination was made
and an electrocardiogram and chest radiographs
obtained for all patients. No patient had a
history suggestive of rheumatic fever or
infective endocarditis, and none was specifically
referred because of suspected valvular abnor-
malities. In those with valve thickening and
nodular vegetations, infective endocarditis was
reasonably ruled out by six negative blood
cultures.
In addition, 40 healthy subjects (36 women,
four men), matched to the patient group for age
and sex (mean age 37 (11) years) served as
controls. All were volunteers with no clinical
evidence of any cardiac or systemic complaints.
Informed consent was obtained from all patients
and controls.
DIAGNOSIS AND CLINICAL ACTIVITY OF SLE
All the patients included in the study fulfilled
the 1982 revised criteria of the American
Rheumatism Association for the classification of
SLE.'4 Average duration of SLE was 63 (54)
months (range 4-254). Individual clinical
156
 group.bmj.com on June 16, 2011 - Published by ard.bmj.comDownloaded from 
Cardiac disease in systemic lupus erythemitosus
features of SLE were considered by a qualified
doctor if they fulfilled the definitions of the
American Rheumatism Association glossary.'5
To assess disease activity all records were
evaluated without knowledge of the echocardio-
graphic findings. Disease was judged to be
clinically active if the following signs or
symptoms were present: typical dermatitis;
arthritis; serositis; central nervous system
abnormalities (recent onset of chorea, seizures,
psychosis, organic brain syndrome in the absence
of offending drugs or known metabolic derange-
ments, embolic cerebral vascular accidents);
thrombocytopenia (<lOOx 109 platelets/l);
haemolytic anaemia; vasculitis (biopsy); or
nephritis (recent onset of haematuria (>10 red
blood cells/high power field), or casts, or
proteinuria (>500 mg/24 h), or a 25% increase
in serum creatinine).
ECHOCARDIOGRAMS
Two dimensional and Doppler echocardiograms
were obtained with a commercially available
phased array ultrasonic sector scanner with a
2 5 MHz transducer. Images were analysed
according to the recommendations of the
American Society of Echocardiography.'6 Two
echocardiologists independently assessed all
studies without knowledge of the patients'
status. In the event of a disagreement, the two
echocardiologists reached a consensus by a joint
review of the study.
LABORATORY STUDIES
Antinuclear antibodies were determined by
indirect immunofluorescence using mouse liver
as substrate. Antibodies to dsDNA were deter-
mined by Farr's ammonium sulphate precipi-
tation technique. Complement components (C3
and C4) were estimated by radial immuno-
diffusion and CH50 by Lachmann's haemolytic
technique. Circulating immune complexes were
detected by a microcomplement consumption
test. Precipitating antibodies to soluble nuclear
and cytoplasmic antigens, including Ro(SSA),
La(SSB), nRNP, and Sm, were determined by
double immunodiffusion (Ouchterlony).
Antibodies to cardiolipin were measured by
an enzyme linked immunosorbent assay
(ELISA) as described by Loizou et al'7 and
Gharavi et al"' with our minor modifications'9
and those ofCowchock et al.20 The flat bottomed
wells of the microtitre plates (Nunc, Denmark)
were coated with 30 [iI/well of cardiolipin
(Sigma) suspended in ethanol at a final concen-
tration of 50 ,ug/ml. The test was modified by
inclusion of a measurement of binding to the
microtitre plates after blocking (with 10% fetal
calf serum in phosphate buffered saline for two
hours) without added cardiolipin. Tests were
performed in duplicate, both with and without
phospholipid. Results were expressed as a
binding index (BI) given by the formula:
BI (specific)=BI (total)-BI (non-specific)
where BI (total)=average value for samples
from the wells containing cardiolipin; BI (non-
specific)=average value for samples from the
wells containing no cardiolipin.
A study of 50 serum samples from normal
controls showed a log-normal distribution of
either IgG or IgM anticardiolipin antibody
titres. Normal values were considered when the
logarithms of the specific BI were below the
98th percentile of cumulative normal distri-
bution. The IgG anticardiolipin antibody
titre was regarded as positive if a specific BI
greater than 2 85 (SD 3-77) was detected. A
specific BI greater than 4-07 (3-90) was defined
as positive for IgM anticardiolipin antibody.
Lupus anticoagulant activity was detected by
the method of Exner et al.2'
STATISTICAL ANALYSIS
Conventional x2 and Fisher's exact tests were
used for analysing qualitative differences,
Student's t test for comparison of means in large
samples of similar variance, and the non-
parametric Mann-Whitney U test in small
samples for comparing age differences between
groups. Statistical significance was defined as
p<005.
Results
ECHOCARDIOGRAPHIC ABNORMALITIES AND
CLINICAL FEATURES OF CARDIOPATHY
Forty patients with SLE (57%) were found to
have echocardiographic abnormalities. There
was no significant difference in sex, age, and
duration of disease between those with and
without echocardiographic abnormalities.
Valvular abnormalities were detected in 31
patients (44%) and in only two controls (5%)
(p<0 001) (table 1). Mitral valve abnormalities
were the most common finding (23/70 (33%)),
with mild or moderate regurgitation the most
common lesion (11/70 (16%) and 6/70 (9%)
respectively). Three patients (4%) had a
morphological echocardiographic pattern
suggestive ofnon-infective verrucous vegetations
affecting the mitral valve. A Doppler pattern of
mitral regurgitation was present in all three
cases. When patients with mitral valve prolapse
Table I Echocardiographic valvular abnormalities in
patients with systemic lupus erythematosus (SLE) and
controls. Results are shown as number (percentage) of
patients
Abnormalities Patients with Controls
SLE (n= 70) (n=40)
Valvular 31(44) 2(5)
Mitral valve 23 (33) 2(5)
Vegetations 3(4) 0
Regurgitation 20 (29) 2 (5)
Mild 11(16) 2 (5)
Moderate 6(9) 0
Severe 3(4) 0
Stenosis 2 (3) 0
Mild 2 (3) 0
Calcification 2(3) 0
Thickening without dysfunction 2 (3) 0
Prolapse 2 (3) 2 (5)
Aortic valve 9(13) 0
Regurgitation 5 (7) 0
Mild 5 (7) 0
Stenosis 1 (1) 0
Mild 1(1) 0
Calcification 4 (6) 0
Thickening without dysfunction 1 (1) 0
Tricuspid valve 4 (6) 0
Regurgitation 4 (6) 0
Mild 4 (6) 0
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and mitral and aortic valve thickening or calci-
fication without concomitant features of valvular
dysfunction were excluded the total number of
lupus patients with significant echocardiographic
valvular lesions was 21 (prevalence 30%).
However, only those with non-infective vegeta-
tions and a further group of five patients with
mitral or aortic valve dysfunctions (11%) had
systolic or diastolic murmurs, or both. No
patient had haemodynamically significant
clinical valve disease.
Pericardial effusion was present in 19 patients
(27%) but in no controls (p<0001) (table 2).
Five (7%) had moderate or severe and 14 (20%)
mild effusion. Only patients with moderate and
severe pericardial effusion had clinical and
electrocardiographic features of pericarditis.
Myocardial abnormalities were found in 14
patients (20%) but in no controls (p<0-001)
(table 3). Clinical features of myocardial
dysfunction, however, were present in only one
patient with an echocardiographic pattern
suggestive of myocarditis.
ECHOCARDIOGRAPHIC ABNORMALITIES AND SLE
ACTIVITY
Systemic lupus erythematosus was active in 39
patients (56%), of whom 26 (67%) had echo-
cardiographic abnormalities, including peri-
cardial effusion (19 patients), non-infective
vegetations (three), mild aortic valve regur-
gitation (two), moderate mitral valve regurgi-
tation (one), mitral valve thickening without
dysfunction (one), and myocarditis (one).
ECHOCARDIOGRAPHIC ABNORMALITIES AND
ANTIPHOSPHOLIPID ANTIBODIES
Antiphospholipid antibodies were detected in
23 patients (33%). Patients with these anti-
bodies had a significantly increased prevalence
of endocardial lesions (15 out of 23 positive,
p<0 05), mainly valvular (mitral or aortic valve)
regurgitation (with or without vegetations) (13
out of 23 positive, p<005), compared with
patients without antiphospholipid antibodies.
No relation between antiphospholipid antibodies
and pericardial or myocardial lesions was found.
Table 2 Echocardiographic pericardial abnormalities in
patients with systemic lupus etythematosus (SLE) and
controls. Results are shown as number (percentage) of
patients
Abnorinalities Patients with Controls
SLE (n= 70) (n=40)
Pericardial effusion 19 (27) 0
Mild 14(20) 0
Moderate 3 (4) 0
Severe 2 (3) 0
Table 3 Echocardiographic myocardial abnormalities in
patients with systemic lupus erythematosus (SLE) and
controls. Results are shown as number (percentage) of
patients
Abnormalities Patients with Controls
SLE (n= 70) (n=40)
Myocardial 14(20) 0
Left ventricle enlargement 7 (10) 0
Left ventricle hypertrophy 6(9) 0
Myocarditis 1(1) 0
Discussion
In this echocardiographic study we found a high
prevalence of cardiac disturbances (40/70
(57%)). Valvular abnormalities, mainly mitral
and aortic dysfunctions, were the most common
finding (21/70 (44%)). No patient had haemo-
dynamically significant clinical valve disease. In
addition, pericardial effusion was a common
echocardiographic finding (19/70 (27%)), but
significant pericardial disease was found in only
5/70 (7%) patients. Conversely, significant
myocardial abnormalities were less common
(14/70 (20%)), and only one patient with an
echocardiographic pattern of myocarditis
developed clinical features of myocardial
dysfunction. Interestingly, most patients with
SLE activity had echocardiographic abnormal-
ities, raising the importance of cardiac disease
in the spectrum of SLE manifestations.
Study of heart valve lesions in SLE is of
paramount importance. Whereas mitral valve
prolapse is commonly found in a normal popu-
lation as well as in patients with SLE, other
valvular dysfunctions, such as non-infective
vegetations and mitral or aortic dysfunctions,
are most commonly found in patients with this
disorder,6'0 as we found in this study. Non-
infective vegetations, first described by Libman
and Sacks in 1924,22 are the most characteristic
valvular lesions of SLE. Microscopically, they
consist of proliferating and degenerating cells,
fibrin, fibrous tissue, and occasional haema-
toxylin bodies. Their most common locations
are at the valve margins and on chordae
tendineae, papillary muscles, and mural
endocardium.1 2 Early reports suggested a
predominance of tricuspid disease, but more
recent series indicate a higher prevalence of
mitral valve vegetations,6'0 as found in our
patients. Although non-infective vegetations in
SLE rarely result in haemodynamically signi-
ficant valve disease, there are a number of
reported cases describing the occurrence of
valvular stenosis and regurgitation as a result of
Libman-Sacks endocarditis.2>25 In fact, most
of the valvular dysfunctions in young lupus
patients without a history of rheumatic fever or
infective endocarditis are probably due to
previous silent Libman-Sacks endocarditis.
Thromboembolism is a rare consequence of
non-infective endocarditis, but pulmonary,
cerebral, and coronary embolisation of tissue
from these sterile vegetations has been docu-
mented.26 In addition, Libman-Sacks endo-
carditis probably predisposes to infective
endocarditis.27
The association ofantiphospholipid antibodies
with venous or arterial thrombosis, or both,
recurrent fetal loss, and thrombocytopenia has
been well documented in several studies.20 2830
It is postulated that antiphospholipid antibodies
may cause these disorders either through
platelet activation by binding to platelet
phospholipids3' or through inhibition of
prostacyclin production in the endothelium.32
Furthermore, there have been several reports of
the possible association of antiphospholipid
antibodies with endocardial lesions, such as
non-infective vegetations and valvular dys-
functions."' 3 In this study we confirmed the
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association of antiphospholipid antibodies with
acquired endocardial disease, including mitral
or aortic valve regurgitation, probably due to
previous silent non-infective endocarditis.
The aetiopathogenesis of these valvular
lesions in SLE and their relation with antiphos-
pholipid antibodies is as yet unknown. Never-
theless, Shapiro et al found selective deposition
of immunoglobulins and complement along the
vessel walls of vegetations,33 suggesting that
circulating immune complexes may participate
in the growth and proliferation of these non-
infective vegetations. The pathogenetic role of
antiphospholipid antibodies remains to be
elucidated, but our results give food for thought
about the possibility that antiphospholipid
antibodies may contribute to the pathogenetic
mechanisms of these valvular lesions by
promoting thrombus formation.
In conclusion, the inclusion of two dimen-
sional and Doppler echocardiography in a study
protocol of patients with SLE can identify an
important subset of patients with cardiac
abnormalities. Clinically significant lesions are
uncommon, however, usually occurring in
patients with SLE activity. In addition, the
finding of an association between antiphos-
pholipid antibodies and endocardial lesions
suggests the possibility of a prominent role for
these antibodies in the pathogenetic mechanisms
of heart valve disease in lupus.
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